UNSPSC 51282526: Cefapirin sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C17H16N3O6S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 431LFF7I7J, chemically known as 5-thia-1-azabicyclo(4,2,0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester), monosodium salt but more generally known as cefapirin sodium, which bears US NIH Compound Identifier 32325.

European Medicines Agency schedules Cefapirin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01103MIG. Most nations, for tariff and trade purposes, schedule cefapirin sodium under HS 29419000. SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3CCNCC3)SC1)C(=O)[O-].[NA+].

UNSPSC 51282526 Cefapirin sodium is a Commodity code for pharmaceutical products, though recent state and local procurement activity under this code shows minimal alignment with the nominal scope—the most recent opportunities posted target different drug products entirely (naloxone, doxycycline, ciprofloxacin) rather than cefapirin specifically. State and local governments do procure pharmaceutical supplies through cooperative purchasing vehicles and direct buys, but the indexed opportunities do not reflect demand for cefapirin sodium itself. When pharmaceutical procurement does occur at the state and local level, it typically flows through established consortiums and piggyback arrangements with large healthcare suppliers and regional health departments managing inventory and distribution to public health facilities.

Recent activity under this code is limited and geographically sparse. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for antibiotic products (closed award, not an open solicitation), and Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems with a July 26, 2026 response deadline. Neither opportunity directly solicits cefapirin sodium. The code shows insufficient recent activity to characterize meaningful geographic concentration or identify repeat buyers focused on this specific pharmaceutical. Firms evaluating this code should verify whether state and local health departments and correctional agencies in their target regions maintain active demand for cefapirin sodium specifically, as indexed procurement records do not surface it as a current buying priority.